Amneal Announces FDA Approval and Launch of Lanreotide Injection

 - Expands complex injectables portfolio with important long-acting oncology treatment
 - Immediate commercial launch supported by in-house production

BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE^® Depot and will launch immediately. The product received Competitive Generic Therapy (CGT) designation from the FDA.